Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

88 results about "Lymphatic tissues" patented technology

Lymphatic Tissue is a specialized form of reticular connective tissue in the lymphatic system that contains large numbers of lymphocytes. This tissue type makes up the spleen, the thymus, and the tonsils, as well as visceral nodes, peyer's patches and lacteals which are all associated with mucous membranes of the gastro-intestinal tract.

Multi-directional oral phototherapy applicator

Oral phototherapy applicators are disclosed that are sized and shaped so as to fit at least partially in a user's mouth and have at least one radiation emitting element coupled to an apparatus body to irradiate a portion of the oral cavity with phototherapeutic radiation along multiple directions. In one aspect, the apparatus is configured to direct radiation to at least one portion of the oral cavity, such as the teeth, cheeks, tongue, palate, throat, lymphatic tissue, blood, glands, follicles, collagen, pigmentation or facial tissue, generally. The apparatus can further include bristles to provide a phototherapeutic toothbrush. Alternatively, the apparatus body can be adapted for placement in a fixed position relative to the oral cavity during phototherapy.
Owner:PALOMAR MEDICAL TECH

Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices

InactiveUS7192769B2Improvement in rate and numberQuick buildCompound screeningApoptosis detectionAntigenStromal cell
The invention relates to a method for lymphoid tissue-specific cell production from hematopoietic progenitor cells in unique, three-dimensional culture devices, in the presence of antigen presenting cells and lymphoreticular stromal cells, and in the absence of exogenously added growth factors. The resulting lymphoid tissue-specific cells may be isolated at any sequential stage of differentiation and further expanded. The lymphoid tissue-specific cells also may be genetically altered at any stage of the process.
Owner:CYTOMATRIX +1

Cd20 antibodies and uses thereof

ActiveUS20110195022A1Improve stabilityImproved ADCC functionAntipyreticAnalgesicsDiseaseCD20
CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.
Owner:IMMUNOGEN INC

Noninvasive vascular therapy

The present invention is drawn to methods and compounds for transcutaneous photodynamic therapy ("PDT") of a target tissue or compositions in a mammalian subject, which includes administering to the subject a therapeutically effective amount of a photosensitizing agent or a photosensitizing agent delivery system or a prodrug where the photosensitizing agent or photosensitizing agent delivery system or prodrug selectively binds to the target tissue; and irradiating at least a portion of the subject with light at a wavelength absorbed by the photosensitizing agent or if prodrug, by a prodrug product thereof where the light is provided by a light source, and where the irradiation is at low fluence rate that results in the activation of the photosensitizing agent or prodrug product. These methods of transcutaneous PDT are useful in the treatment of specifically selected target tissues, such as: vascular endothelial tissue abnormal vascular wall of tumors; tumors of the head and neck; tumors of the gastrointestinal tract; tumors of the liver; tumors of the esophopharyngeal; tumors of the lung; lymphoid tissue; lesions in the vascular system; hone marrow and tissue related to autoimmune disease.
Owner:LIGHT SCI ONCOLOGY

Skincare device

The invention is of various portable, handheld, electronic skincare devices with exterior regions that are configured to engage human skin in a manner that provides a benefit to the skin and / or to tissue proximate to the skin. The exterior regions are configured to vibrate, heat, cool, sense, and / or stimulate the skin. The generated and applied vibrations may be of predetermined and different waveforms configured to achieve a particular result, such as, applying a skincare product to the skin or loosening an element from the skin. The exterior regions may be: a plurality of touch-points, a smooth-plate, and / or a rounded and smooth base. The benefit may be of: cleansing, massaging, soothing, relaxing, loosening of sinus pressure, application of skincare product to skin, removal of skincare product from the skin, opening of skin pores, closing of skin pores, heating, cooling, wrinkle reduction, massaged lymphatic tissue, and / or drained lymphatic tissue.
Owner:QYK BRANDS LLC

System and Method for Targeted Delivery of Therapeutic Agents to Tissue

Novel systems for and methods of delivering therapeutic agents to target tissues are disclosed. The method of delivering a therapeutic agent to a target tissue involves identifying a target tissue via an imaging modality and then using a guidewire capable of anchoring in tissue to advance a cannula to the target tissue. The guidewire and novel cannula configurations enable rapid and repeated treatments of the target tissue without the need for subsequent imaging. The cannula is coupled to a source of ultrasound, radiation, radiofrequency energy, or chemotherapeutic agents which can then be delivered to from the cannula the target tissue. The system and method can be used to treat tumors that are small or surgically inoperable. In addition, the system can be used to treat lymphatic tissue that may contain metastases from the tumors.
Owner:ETHICON INC

Diagnostic and therapeutic uses for prox 1

Methods and compositions based on the elucidation of the role of Prox1 in lymphatic tissue development in normal and tumor tissue are provided. Included are methods for determining the extent of lymphatic involvement in a tumor, methods for purifying endothelial precursor cells predisposed to develop into lymphatic tissue, and methods for promoting the development of lymphatic tissue. Pharmaceutical compositions and gene therapy vectors useful in the latter methods are provided.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC

Deep learning-based lymphoma pathological image intelligent identification method

The invention discloses a deep learning-based lymphoma pathological image intelligent identification method. The method comprises the steps of preprocessing lymphoma pathological section image data; constructing a full convolutional neural network for segmenting a lymphatic tissue region, wherein the full convolutional neural network comprises an encoder sub-network and a decoder sub-network; constructing a lymphoma three-classification convolutional neural network under high resolution, wherein the lymphoma three-classification convolutional neural network is composed of six convolutional layers and three full-connection layers which are connected in sequence; and training the full convolutional neural network and the lymphoma three-classification convolutional neural network to finally obtain a lymphoma pathological section image classification model, and sequentially passing through the full convolutional neural network and the lymphoma three-classification convolutional neural network during testing to finally obtain a lymphoma classification result. Reliable intermediate data are provided for pathologists to judge lymphoma subtype categories, and auxiliary diagnosis referenceis provided for the pathologists to classify lymphoma subtypes by analyzing digitally scanned lymphoma pathological images, so that the pathologists are helped to quickly judge lymphoma conditions ofpatients.
Owner:天津深析智能科技有限公司

Recombinant oncolytic II-type herpes simplex virus (HSV) and pharmaceutical composition thereof

The invention discloses a recombinant oncolytic II-type herpes simplex virus (HSV) and a pharmaceutical composition thereof. Two ICP34.5 genes and one ICP47 gene are knocked out of a genome of the recombinant oncolytic II-type HSV, human telomerase chemotactic gene SLC-Te-Fc expression boxes are respectively inserted into sites of the two ICP34.5 genes, and the human telomerase chemotactic gene SLC-Te-Fc expression boxes are orderly connected to a CMV promoter, a secondary lymphoid tissue chemotactic factor SLC, a telomerase Te (named as TERT), an immune globulin Fc segment and a bovine growth hormone polyadenosine sequence BGHpA. Oncolytic HSV has strong oncolytic effects, can be used as a gene carrier, and can carry and highly express tumor-related antigens to form a therapeutic immune gene vaccine. Through combination, the problem that the single oncolytic HSV cannot greatly induce specific antineoplastic immunization is solved.
Owner:刘滨磊

Techniques for neuromodulation

ActiveUS20190117977A1Increase in a subject's tissueImplantable neurostimulatorsMagnetotherapyReflexMedicine
The subject matter of the present disclosure generally relates to techniques for neuromodulation of lymphatic tissue that include applying one or more energy pulses to a neuron of a subject, e.g., via an electrode positioned to deliver sufficient energy to the neuron, to modulate immune function. For example, an adaptive immune reflex of a subject may be modulated via neuromodulation
Owner:GENERAL ELECTRIC CO

Face-thinning appearance-lifting compound essential oil

A face-thinning appearance-lifting compound essential oil comprises the following plant essential oils: by volume, 4-10 parts of juniper berry essential oil, 4-8 parts of lavender essential oil, 2-6 parts of rosemary essential oil, 2-5 parts of grapefruit essential oil, 3-6 parts of fennel essential oil, 2-5 parts of cypress essential oil and 400-800 parts of jojoba oil. Through utilization of strong penetration of various aromatic plant essential oils, the face-thinning appearance-lifting compound essential oil can rapidly permeate skins to arrive to subcutaneous fat layers, can effectively burn fat, can decompose excess lactic acid, can stimulate lymphatic activity, can promote blood circulation, can increase cortical metabolism ability, can make excess fat and moisture to discharge, and can improve cellulite. The face-thinning appearance-lifting compound essential oil can burn excess facial fat, eliminate proud flesh, firm skins, promote capillaries and metabolism, improve lymph tissues, promote discharge of excess facial moisture and toxins, and locally thin a face. The face-thinning appearance-lifting compound essential oil has an obvious declination effect on faciocervical fat, can tighten the skins, dispel the excess facial fat, and tighten loose facial skins to rebuild a perfect profile.
Owner:SUZHOU NATESU BIOLOGICAL SCI & TECH

2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists

The present invention encompasses compounds of Formula I:as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1 / Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.
Owner:MERCK SHARP & DOHME CORP

Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues

The present invention relates to compositions and methods of inhibiting stem cell binding to organs and tissues, including the blocking of stem cell binding to germinal centers present in lymph tissue. Disclosed are compositions and methods for regenerating germinal centers in lymphatic tissue. Included in the compositions are adjuvants, agonists to CD40, CD28 and the IL-21 receptor, and antagonist to CD20.
Owner:AVM BIOTECH

Methods and compositions for polytopic vaccination

The present invention relates to therapeutic and prophylactic methods for treating or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject.
Owner:POLYTOPOS

In vivo visualization of lymphatic tissue

ActiveUS20140121512A1Facilitate high volume deliveryEasy and straightforward to assessSurgeryDiagnostics using fluorescence emissionLymphatic vesselFluorescence
Aspects of the invention include methods for visualizing lymphatic tissue in an ocular region, e.g., the cornea, of a living subject, such as a mouse or human. In certain embodiments, the methods include contacting the region with a fluorescently-labeled lymphatic tissue-specific dye, e.g., FITC or rhodamine labeled dextran, and detecting the labeled dye to visualize lymphatic tissue in the region, where the visualization may vary, from an image obtained at a single time to a video over a period of time. The invention finds use in a variety of different applications, including research and therapeutic applications.
Owner:RGT UNIV OF CALIFORNIA

Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide

Disclosed are methods for the prevention or treatment of a disease or infection caused by or associated with H. Pylori in a subject infected by H. Pylori, the method comprising orally administering a halogenated salicylanilide such as niclosamide to the subject. The method may be used for the prevention or treatment of, for example dyspepsia, gastritis, peptic ulcer disease, premalignant gastric lesions, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Owner:RHODE ISLAND HOSPITAL

New application of injection omeprazole sodium for treating gastric mucosa-associated lymphoid tissue lymphoma

The invention relates to new application of injection omeprazole sodium for treating gastric mucosa-associated lymphoid tissue lymphoma. The injection omeprazole sodium for treating gastric mucosa-associated lymphoid tissue lymphoma comprises omeprazole sodium, filling agent, metallic ion complexing agent, antioxidant and pH regulator. The invention has the advantages of stable characters and color, little side effects, high security, good stability and favorable resolubility, and has higher content of omeprazole sodium than that of the common omeprazole sodium injection.
Owner:邓菊娟

CD20 antibodies and uses thereof

CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 17-19, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 20-22, respectively.
Owner:IMMUNOGEN INC

ALK protein tyrosine kinase, cells and methods embodying and using same

The present invention provides for a transgenic animal model that constitutively expresses a protein encoded by the NPM-ALK gene in lymphoid tissue, and exhibits enhanced and accelerated development of a T cell lymphoproliferative disorder or B cell plasma cell tumor, together with the identification of cells transduced with the ALK tyrosine kinase gene or fusion proteins thereof, and methods for using this animal model and cells for screening compounds or treatments for antitumor activity. In preferred embodiments, the animal is a transgenic mouse that expresses a human NPM-ALK gene operably linked to human regulatory sequences, and the cells of the mouse have at least one copy of the NPM-ALK transgene, whereby the mouse constitutively expresses a protein encoded by the NPM-ALK transgene. The animals and cells of the invention are useful in the study of NPM-ALK-dependent lymphomagenesis and plasma cell tumors and in the development of treatments for these conditions.
Owner:NEW YORK UNIV

Mucosal membrane receptor and uses thereof

The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic E. coli (ETEC). Based on the observation that oral administration of F4 fimbriae induces a protective intestinal mucosal immune response against a subsequent challenge with F4 ETEC, and the observation that the internalization of said F4 fimbriae is clathrin-mediated, the present invention provides the characterization of APN as a target useful in: in an in vitro assay to screen for molecules that are capable to mimic the clathrin-mediated F4 endocytosis; in an in vitro assay to screen for molecules that are capable to modulate the binding of F4 fimbriae with APN; in the development of a carrier for the delivery of antigens / therapeutics, i.e. immunomodulators to the intestinal submucosa or the intestinal mucosa-associated lymphoid tissue, wherein said carrier comprises an APN specific target molecule that mimics the clathrin-mediated F4 endocytosis. The use of the carriers thus identified or the treatments thus identified, in a method of inducing an antigen specific intestinal mucosal immune response, and / or in the treatment of bacterial diarrhea, is a further aspect of the present invention.
Owner:UNIV GENT

Chimeric antigen receptor-T cells secreting and expressing IL15RA-IL15 fusion proteins and CCL21 chemotactic factors, and applications thereof

The invention discloses chimeric antigen receptor-T cells secreting and expressing IL15RA-IL15 fusion proteins and CCL21 chemotactic factors as well as application thereof. Super IL15 can promote activation and proliferation of T (especially memory T) cells, NK cells and NKT cells; and CCL21 can recruit peripheral CCR7-positive initial T cells, memory T cells and dendritic cells (DC) into lymphoidtissue or tumor lesions so as to activate active anti-tumor immune response (such as cancer memory T cells) in the body, thereby significantly improving efficiency and remission rate, as well as reducing recurrence rate after remission.
Owner:浙江启新生物技术有限公司

Preparation method of lymph node tissue slice

ActiveCN109580306AAccurate Pathological DiagnosisAnatomical integrity protectionPreparing sample for investigationWaxLymph Node Tissue
The invention discloses a preparation method of lymph node tissues slices. Adipose tissues are attached around and / or inside the lymph node tissues. The method comprises the following steps of: fixing, dehydrating, transparenting, wax soaking, embedding, slicing, and staining the lymph node tissues, wherein a step of treating the lymph node tissues with an alkaline solution is also included between the step of fixing and the step of dehydrating. According to the preparation method of the lymph node tissues slices, the lymph node tissues are treated with the alkaline solution to remove lipid droplets in fat cells, so that the adipose tissue and the lymphatic tissue achieve the same dewatering effect, and thus the whole continuous piece is sliced. In addition, using the method for treating the adipogenic area in the lymph nodes, a void phenomenon can be generated when slicing to obtain high-quality slices.
Owner:CENT SOUTH UNIV

Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues

The present invention relates to compositions and methods of inhibiting stem cell binding to organs and tissues, including the blocking of stem cell binding to germinal centers present in lymph tissue. Disclosed are compositions and methods for regenerating germinal centers in lymphatic tissue. Included in the compositions are adjuvants, agonists to CD40, CD28 and the IL-21 receptor, and antagonist to CD20.
Owner:AVM BIOTECH

Lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as carrier and preparation method and application of lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as carrier

The invention relates to contrast agents for medical science, in particular to a lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as a carrier and a preparation method and application of the lymph targeted nuclear magnetic resonance imaging contrast agent with the brown algal polysaccharide serving as the carrier. The macromolecular contrast agent high in water solubility is prepared by taking the brown algal polysaccharide as the carrier, taking mannose or mannose derivatives as a mannose receptor MBP (mannose binding protein) recognition group and taking paramagnetic metal ion chelates as a nuclear magnetic resonance imaging group. Lymph tissue binding force is increased, and combination of the mannose or mannose derivative group introduced into the synthetic contrast agent with mannose receptors enriched in lymph tissues is realized. In addition, after hypodermic injection of the contrast agent, lymph vessels and lymph glands are clearly developed under scanning of a nuclear magnetic resonance equipment, lymph gland signal enhancement rate of one side, with the contrast agent injected, of an animal body is remarkably increased while enhancement time is remarkably prolonged, distinct drawing and precise positioning of the lymph glands and the lymph vessels are realized, and a great significance to examination and diagnosis of lymphatic diseases is achieved.
Owner:OCEAN UNIV OF CHINA

Neurology clinic treatment system

The invention relates to the technical field of medical instruments, in particular to a neurology clinic treatment system which comprises a main box. A central processing unit is embedded into the topend of the front side of the main box, an instrument storage box is embedded into the bottom end of the front side of the main box, and a back treatment device comprises an arc-shaped plate. According to the neurology clinic treatment system, a head of a patient can be automatically massaged through a head cover in a head treatment device, electrical stimulation treatment can be achieved, the height can be adjusted according to conditions such as different heights of patients, low-frequency pulse fluctuation and intermediate frequency electrotherapy is performed on the patients through acupuncture magnets in the back treatment device, backs and lungs are vibrated by vibration supports, phlegm stasis of the patients can be removed, flow of venous blood and lymphatic tissue fluid of legs can be accelerated by rotation of balls in a leg treatment device, and blood supply of arteries is improved. The neurology clinic treatment system complete in function, a plurality of functions can be simultaneously used, time and labor are saved, and the working efficiency of doctors is improved.
Owner:韩增灿

Method for detecting short-chain fatty acids in serum and lymphatic tissues based on GC-MS

The invention discloses a method for detecting short-chain fatty acids in serum and lymphatic tissues based on GC-MS. The method comprises the following steps: pretreating lymphatic tissues to obtaina lymphatic extracting solution; adding an internal standard substance into the serum or lymph extracting solution, and adding benzyl pentafluorobromide for derivatization reaction; and extracting thederived solution, and detecting acetic acid, propionic acid and butyric acid in the extract by using GC-MS. A gas chromatography-mass spectrometry rapid determination method for detecting three short-chain fatty acids in the serum and lymphatic tissues is established through a derivatization method. Different biological samples are pretreated and subjected to derivatization treatment, the internal standard is added for correction and accurate quantification is achieved.
Owner:SHANDONG SHANWEI IMMUNOTECH CO LTD

Blood vessel protection belt and preparation method and application thereof

The invention discloses a blood vessel protection belt and a preparation method and application thereof. The blood vessel protection belt is coiled by a long-strip-shaped collagen thin film or a long-strip-shaped collagen composite thin film. The blood vessel protection belt is applied to isolation of blood vessels and tissue liquid, the blood vessels are subjected to skeletonization dissection, and the tissue liquid is abdominal pus or digestive juice after radical excision surgery of hepatic-biliary-pancreatic malignant tumors. For the first time, it is proposed that the strip-shaped collagen film and the strip-shaped collagen composite film are used as the blood vessel protection belt, and the blood vessel protection belt is used for the radical excision surgery of gastrointestinal tumors, especially the hepatic-biliary-pancreatic malignant tumors, is wound around the arteriovenous blood vessels subjected to skeletonization lymphatic tissue dissection, conducts isolation protectionon the blood vessels, and prevents the abdominal pus or the digestive juice leaking from anastomotic stoma from corroding the blood vessels and then causing hemorrhage.
Owner:何浩明 +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products